<i>JAK3</i> ^A573V and <i>JAK3</i> ^M511I mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3/PD-L1 pathway.

ABSTRACT:

Background

Clinical evidence has established anti-PD-1 antibody as a transformative treatment modality for relapsed/refractory peripheral T-cell lymphoma (r/r PTCL), yet reveals a therapeutic plateau with drug resistance observed in 60% of r/r PTCL. The biological determinants underlying this resistance-particularly the complex interplay between tumor-intrinsic characteristics (including tumor mutation burden and oncogenic mutations) and immune microenvironment features (notably PD-L1 expression)-remain insufficiently illustrated. Therefore, we systematically depicted the comprehensive mutation profile of r/r PTCL patients and correlated them with the efficacy and prognosis of anti-PD-1 therapy.

Methods

Here, we enrolled a cohort of 109 patients with r/r PTCL and performed t

SUBMITTER: Lou N 

PROVIDER: S-EPMC11979606 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature